BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Peng J, Huang J, Huang G, Zhang J. Predicting the Initial Treatment Response to Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma by the Integration of Radiomics and Deep Learning. Front Oncol 2021;11:730282. [PMID: 34745952 DOI: 10.3389/fonc.2021.730282] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Sun Z, Shi Z, Xin Y, Zhao S, Jiang H, Li J, Li J, Jiang H. Contrast-Enhanced CT Imaging Features Combined with Clinical Factors to Predict the Efficacy and Prognosis for Transarterial Chemoembolization of Hepatocellular Carcinoma. Acad Radiol 2023:S1076-6332(22)00687-0. [PMID: 36803649 DOI: 10.1016/j.acra.2022.12.031] [Reference Citation Analysis]
2 Qu H, Zhai H, Zhang S, Chen W, Zhong H, Cui X. Dynamic radiomics for predicting the efficacy of antiangiogenic therapy in colorectal liver metastases. Front Oncol 2023;13:992096. [PMID: 36814812 DOI: 10.3389/fonc.2023.992096] [Reference Citation Analysis]
3 Wei J, Jiang H, Zhou Y, Tian J, Furtado FS, Catalano OA. Radiomics: A radiological evidence-based artificial intelligence technique to facilitate personalized precision medicine in hepatocellular carcinoma. Dig Liver Dis 2023:S1590-8658(22)00863-5. [PMID: 36641292 DOI: 10.1016/j.dld.2022.12.015] [Reference Citation Analysis]
4 Xu Q, Wang C, Yin G. Immune-related gene signature to predict TACE refractoriness in patients with hepatocellular carcinoma based on artificial neural network. Front Genet 2022;13:993509. [PMID: 36685822 DOI: 10.3389/fgene.2022.993509] [Reference Citation Analysis]
5 Wong PK, Chan IN, Yan HM, Gao S, Wong CH, Yan T, Yao L, Hu Y, Wang ZR, Yu HH. Deep learning based radiomics for gastrointestinal cancer diagnosis and treatment: A minireview. World J Gastroenterol 2022; 28(45): 6363-6379 [DOI: 10.3748/wjg.v28.i45.6363] [Reference Citation Analysis]
6 Peng J, Zhang J, Zou D, Xiao L, Ma H, Zhang X, Li Y, Han L, Xie B. Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1/PD-L1 blockade. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.960459] [Reference Citation Analysis]